{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:05:59Z","timestamp":1794539159973,"version":"4.9.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify possible differences in baseline characteristics, initial treatment and treatment response between RA patient subgroups based on age at disease onset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Daily practice data from the worldwide METEOR registry were used. Patients (7912) were stratified into three age-groups (age at disease diagnosis &amp;lt;45\u2009years, 45\u201365\u2009years, &amp;gt;65\u2009years). Initial treatment was compared between the different age-groups. With Cox regression analyses the effect of age-group on time-to-switch from first to second treatment was investigated, and with linear mixed models differences in response to treatment (DAS and HAQ) between the age-groups were assessed, after correction for potential confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The &amp;gt;65\u2009years age-group included more men, and more seronegative RA with somewhat higher inflammatory markers. Initial treatment choices differed only slightly between the age-groups, and the time-to-switch from initial treatment to the next was similar. DAS and HAQ improvement were dependent on the age-group, reflected by a significant interaction between age-group and outcome. The stratified analysis showed a difference of \u22120.02 and \u22120.05 DAS points and, \u22120.01 and 0.02 HAQ points per month in the &amp;lt;45 and 45\u201365\u2009years age-groups as compared with the &amp;gt;65\u2009year age group, a difference that did not seem clinically relevant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this international study on worldwide clinical practice, patients with RA onset &amp;gt;65\u2009years include more men and seronegative arthritis, and were initially treated slightly differently than younger patients. We observed no clinically relevant differences in timing of a next treatment step, or response to treatment measured by DAS and HAQ.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab102","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T16:31:01Z","timestamp":1611851461000},"page":"4801-4810","source":"Crossref","is-referenced-by-count":21,"title":["Phenotype and treatment of elderly onset compared with younger\u2002onset rheumatoid arthritis patients in international daily practice"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9591-5398","authenticated-orcid":false,"given":"Johanna M","family":"Maassen","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-5248","authenticated-orcid":false,"given":"Sytske Anne","family":"Bergstra","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Chopra","sequence":"additional","affiliation":[{"name":"Center for Rheumatic Diseases, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimmisha","family":"Govind","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Murphy","sequence":"additional","affiliation":[{"name":"University Hospital Wishaw, Wishaw, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vega-Morales","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario \u2018Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u2019, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom W J","family":"Huizinga","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia F","family":"Allaart","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"2021100217522945400_keab102-B1","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.4065\/78.12.1564","article-title":"Principles of drug therapy for the elderly patient","volume":"78","author":"Bressler","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"2021100217522945400_keab102-B2","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/ard.2005.051144","article-title":"Do patients with older-onset rheumatoid arthritis receive less aggressive treatment?","volume":"65","author":"Tutuncu","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2021100217522945400_keab102-B3","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3899\/jrheum.141534","article-title":"Treatment patterns of multimorbid patients with rheumatoid arthritis: results from an international cross-sectional study","volume":"42","author":"Radner","year":"2015","journal-title":"J Rheumatol"},{"key":"2021100217522945400_keab102-B4","first-page":"1285","article-title":"Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis","volume":"18","author":"van der Heijde","year":"1991","journal-title":"J Rheumatol"},{"key":"2021100217522945400_keab102-B5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1759720X17740075","article-title":"An autumn tale: geriatric rheumatoid arthritis","volume":"10","author":"Kobak","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2021100217522945400_keab102-B6","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar4540","article-title":"Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study","volume":"16","author":"Innala","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2021100217522945400_keab102-B7","first-page":"256","article-title":"Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a matched-pairs analysis taking age and disease duration into account","volume":"31","author":"Huscher","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2021100217522945400_keab102-B8","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.3899\/jrheum.160051","article-title":"Differences in predictive factors for sustained clinical remission with abatacept between younger and elderly patients with biologic-naive rheumatoid arthritis: results from the ABROAD study","volume":"43","author":"Sekiguchi","year":"2016","journal-title":"J Rheumatol"},{"key":"2021100217522945400_keab102-B9","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/rheumatology\/key165","article-title":"Management of inflammatory rheumatic conditions in the elderly","volume":"58","author":"Lahaye","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2021100217522945400_keab102-B10","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021100217522945400_keab102-B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021100217522945400_keab102-B12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archinte.1993.00410020091008","article-title":"Reporting of age data in clinical trials of arthritis. Deficiencies and solutions","volume":"153","author":"Rochon","year":"1993","journal-title":"Arch Intern Med"},{"key":"2021100217522945400_keab102-B13","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/acr.22646","article-title":"Epidemiology and treatment of new-onset and established rheumatoid arthritis in an insured US Population","volume":"67","author":"Crane","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021100217522945400_keab102-B14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.semarthrit.2018.07.009","article-title":"Efficacy and safety of biological agents in the older rheumatoid arthritis patients compared to Young: a systematic review and meta-analysis","volume":"48","author":"Dalal","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2021100217522945400_keab102-B15","first-page":"S87","article-title":"Ten years of METEOR (an international rheumatoid arthritis registry): development, research opportunities and future perspectives","volume":"34","author":"Bergstra","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2021100217522945400_keab102-B16","first-page":"579","article-title":"Development of a disease activity score based on judgment in clinical practice by rheumatologists","volume":"20","author":"van der Heijde","year":"1993","journal-title":"J Rheumatol"},{"key":"2021100217522945400_keab102-B17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2021100217522945400_keab102-B18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jbspin.2015.09.010","article-title":"Effect of age at rheumatoid arthritis onset on clinical, radiographic, and functional outcomes: the ESPOIR cohort","volume":"83","author":"Krams","year":"2016","journal-title":"Jt Bone Spine"},{"key":"2021100217522945400_keab102-B19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10067-016-3481-9","article-title":"Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey","volume":"36","author":"Ramos-Remus","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2021100217522945400_keab102-B20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10067-014-2750-8","article-title":"Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis","volume":"34","author":"Nakajima","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2021100217522945400_keab102-B21","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3899\/jrheum.150828","article-title":"Age and comorbidities influence initial treatment of patients with early rheumatoid arthritis","volume":"43","author":"Vega-Morales","year":"2016","journal-title":"J Rheumatol"},{"key":"2021100217522945400_keab102-B22","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/rheumatology\/kep129","article-title":"Missed opportunities in the treatment of elderly patients with rheumatoid arthritis","volume":"48","author":"Radovits","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2021100217522945400_keab102-B23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0049-0172(94)90087-6","article-title":"Elderly-onset rheumatoid arthritis","volume":"23","author":"van Schaardenburg","year":"1994","journal-title":"Semin Arthritis Rheum"},{"key":"2021100217522945400_keab102-B24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/art.1780280905","article-title":"The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration","volume":"28","author":"Deal","year":"1985","journal-title":"Arthritis Rheum"},{"key":"2021100217522945400_keab102-B25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/rheumatology\/35.5.453","article-title":"Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis","volume":"35","author":"Bologna","year":"1996","journal-title":"Br J Rheumatol"},{"key":"2021100217522945400_keab102-B26","first-page":"1298","article-title":"The assessment and prediction of functional disability in rheumatoid arthritis","volume":"18","author":"Wolfe","year":"1991","journal-title":"J Rheumatol"},{"key":"2021100217522945400_keab102-B27","first-page":"218","article-title":"The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group","volume":"22","year":"1995","journal-title":"J Rheumatol"},{"key":"2021100217522945400_keab102-B28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2165\/00002512-200926050-00003","article-title":"Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment","volume":"26","author":"Alivernini","year":"2009","journal-title":"Drugs Aging"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab102\/36185709\/keab102.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/10\/4801\/40500427\/keab102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/10\/4801\/40500427\/keab102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T13:55:13Z","timestamp":1633182913000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/10\/4801\/6127530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,2,4]]},"published-print":{"date-parts":[[2021,10,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab102","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,2,4]]}}}